| Theme | An up-to-date review of the molecular-targeted therapies for inflammatory bowel disease | |
|---|---|---|
| Title | Biologics, small molecule compounds, and malignancy | |
| Publish Date | 2021/09 | |
| Author | Teppei Omori | Department of Gastroenterology, Tokyo Women's Medical University |
| Author | Yu Sasaki | Department of Gastroenterology, Tokyo Women's Medical University |
| Author | Miki Koroku | Department of Gastroenterology, Tokyo Women's Medical University |
| Author | Harutaka Kambayashi | Department of Gastroenterology, Tokyo Women's Medical University |
| Author | Shun Murasugi | Department of Gastroenterology, Tokyo Women's Medical University |
| Author | Maria Yonezawa | Department of Gastroenterology, Tokyo Women's Medical University |
| Author | Katsutoshi Tokushige | Department of Gastroenterology, Tokyo Women's Medical University |
| [ Summary ] | The treatment of patients with IBD complicated by malignancy is not the same as conventional therapy. In particular, continued treatment with biologics and low-molecular-weight compounds may suppress tumor immunity, and it is necessary to discuss the risks and benefits with the oncologist to determine whether the treatment should be continued. In addition, it is necessary to understand the combination of chemotherapy and the general condition of the patient, and to provide optimal medical care that involves various medical staffteams. Despite growin evidence, there is still a lack of long-term follow-up data for new agents, and some biologic agents are supported only by clinical trial data. In addition, the effects of biologics and low-molecularweight compounds on malignant tumors must be examined with consideration given to differential evidence gathered from Europe, the US, or Japan, on account of race, among other factors. | |